RxDoctor Payments Data

Afton Dickerson, NP

Acute Care · Houston, TXNPI 1497387393

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $23,289 of the $27,390 with a category attached, or 85.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,390in general payments, 2019–2025

Across 854 payments — averaging $32.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • Johnson & Johnson$2K
  • AstraZeneca$2K
  • Merck$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Bristol Myers Squibb$1K
  • plus $15K from 54 others

What the payments were for

  • Food & beverage$23,28985%
  • Education$1,7546%
  • Other$2,3479%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis96$3,710
Johnson & Johnson(2 entities)70$2,166
AstraZeneca(2 entities)48$1,914
Merck54$1,518
E.r. Squibb & Sons, L.L.C.41$1,512
Bristol Myers Squibb49$1,279
AbbVie27$1,080
Eisai Inc.29$984
GSK22$845
Sanofi30$826
Astellas Pharma US Inc22$775
Lilly USA, LLC23$738
Incyte Corporation22$646
Seagen Inc.19$630
Amgen21$550
Gilead12$505
Genentech USA, Inc.17$454
Pfizer12$333
Takeda Pharmaceuticals U.S.A., Inc.15$326
Jazz Pharmaceuticals Inc.9$320
Deciphera Pharmaceuticals Inc.12$319
Rigel Pharmaceuticals, Inc.13$319
Sobi, Inc6$308
Springworks Therapeutics, Inc.15$300
Bayer13$294
Regeneron Healthcare Solutions, Inc.4$278
Pharmacyclics LLC, An Abbvie Company10$272
Morphosys, US Inc.11$223
Janssen Scientific Affairs, LLC2$222
Taiho Oncology, Inc.11$205
Beigene USA, Inc.4$204
Pharmaessentia USA Corporation8$195
Daiichi Sankyo Inc.5$190
Myriad Genetic Laboratories, Inc.2$187
Karyopharm Therapeutics Inc.4$171
Pharmacosmos Therapeutics Inc.3$165
Ipsen Biopharmaceuticals, Inc7$152
Immunocore Limited3$148
Puma Biotechnology, Inc.4$134
Apellis Pharmaceuticals, Inc.5$129
Adaptive Biotechnologies Corporation6$124
TG Therapeutics, Inc.2$122
CTI Biopharma Corp.5$120
Sanofi-aventis U.S. LLC2$115
BTG International Inc.1$97
Exelixis Inc.5$88
Blueprint Medicines Corporation3$80
Array Biopharma Inc3$79
Geron Corporation3$76
Servier Pharmaceuticals LLC4$76
Mirati Therapeutics, Inc.4$70
ADC Therapeutics America, Inc.3$68
Stemline Therapeutics Inc.3$66
G1 Therapeutics, Inc.3$65
Myovant Sciences Inc.2$55
ASD Specialty Healthcare, LLC1$49
Alnylam Pharmaceuticals Inc.2$46
Boston Scientific2$45
Tempus AI, Inc2$44
Kyowa Kirin, Inc.2$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,390 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$17,363
Medicare patients
96
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib21$312,404
TasignaNilotinib Hcl15$302,124
VenclextaVenetoclax29$191,881
ImbruvicaIbrutinib11$171,687
XareltoRivaroxaban46$55,379
EliquisApixaban46$34,996
Exemestane41$7,459
Enoxaparin Sodium14$6,975
Famciclovir27$1,687
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine27$655
Hydroxyurea21$477
Anastrozole16$472
Letrozole19$442
Escitalopram Oxalate16$314
Ondansetron OdtOndansetron14$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$738$312,40421 claims
NovartisTasigna$3,710$302,12415 claims
AbbVieVenclexta$1,080$191,88129 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$272$171,68711 claims
Johnson & JohnsonXarelto$2,166$55,37946 claims
PfizerEliquis$333$34,99646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.

Other acute care in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →